ORBIMED ADVISORS LLC 13D and 13G filings for Ikena Oncology, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
2023-09-21 4:52 pm Sale | 2023-08-04 | 13D | Ikena Oncology, Inc. IKNA | ORBIMED ADVISORS LLC | 2,189,111 5.200% | -153,121 (-6.54%) | Filing |
2023-09-14 4:21 pm Purchase | 2023-08-04 | 13D | Ikena Oncology, Inc. IKNA | ORBIMED ADVISORS LLC | 2,342,232 5.500% | 405,346 (+20.93%) | Filing |
2021-08-16 4:45 pm Unchanged | 2021-08-12 | 13D | Ikena Oncology, Inc. IKNA | ORBIMED ADVISORS LLC | 1,936,886 5.400% | 0 (Unchanged) | Filing |
2021-04-14 7:31 pm Purchase | 2021-03-30 | 13D | Ikena Oncology, Inc. IKNA | ORBIMED ADVISORS LLC | 1,936,886 6.560% | 1,936,886 (New Position) | Filing |